Oculis to Present Licaminlimab Data at Eyecelerator, Partner Neuro-Ophthalmology Event

Oculis Holding AG will present data on its licaminlimab drug at Eyecelerator and partner with the Neuro-Ophthalmology Subspecialty Day. The company's PREDICT-1 trial for dry eye disease is on track for topline results around year-end.